Targeting Small Bowel Receptors to Treat Constipation and Diarrhea
- PMID: 28593453
- DOI: 10.1007/s11894-017-0573-x
Targeting Small Bowel Receptors to Treat Constipation and Diarrhea
Abstract
Background: The options for the treatment of diarrhea and constipation are evolving as emerging therapies target small bowel receptors. The goal of this review is to discuss small bowel receptors involved in intestinal absorption, secretion, and motility. The review highlights therapies already approved or currently being studied for the modulation of these receptors.
Methods: The articles cited in this review focus on the molecular level of pathways involved in diarrhea and constipation, and highlight the respective pharmacotherapies.
Results: The majority of the studies in the current literature investigate the effects of both the small and large intestine receptors on diarrhea and constipation. There are fewer studies that isolate the effects of these receptors solely on the small bowel, and focusing more on the receptors found distinctly in the small intestine may be an area of interest for future studies as this can inspire more targeted therapies.
Keywords: Constipation; Diarrhea; Gastroenterology; Small bowel receptors; Small intestine.
Similar articles
-
Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.Am J Med Sci. 2016 Sep;352(3):231-8. doi: 10.1016/j.amjms.2016.05.012. Epub 2016 May 24. Am J Med Sci. 2016. PMID: 27650225
-
Existing and emerging therapies for managing constipation and diarrhea.Curr Opin Pharmacol. 2017 Dec;37:158-166. doi: 10.1016/j.coph.2017.10.015. Epub 2017 Nov 21. Curr Opin Pharmacol. 2017. PMID: 29172123 Free PMC article. Review.
-
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27. Pharmacotherapy. 2015. PMID: 26016701 Review.
-
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444393 Review.
-
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.Neurogastroenterol Motil. 2016 Jan;28(1):26-35. doi: 10.1111/nmo.12716. Neurogastroenterol Motil. 2016. PMID: 26690872 Review.
Cited by
-
Paracellular Filtration Secretion Driven by Mechanical Force Contributes to Small Intestinal Fluid Dynamics.Med Sci (Basel). 2021 Feb 9;9(1):9. doi: 10.3390/medsci9010009. Med Sci (Basel). 2021. PMID: 33572202 Free PMC article.
-
Action Mode of Gut Motility, Fluid and Electrolyte Transport in Chronic Constipation.Front Pharmacol. 2021 Jul 27;12:630249. doi: 10.3389/fphar.2021.630249. eCollection 2021. Front Pharmacol. 2021. PMID: 34385914 Free PMC article. Review.
-
TMAO is involved in kidney-yang deficiency syndrome diarrhea by mediating the "gut-kidney axis".Heliyon. 2024 Jul 30;10(15):e35461. doi: 10.1016/j.heliyon.2024.e35461. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170478 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical